Sumeet Bagadia of Choice Broking has chosen Cipla as his ‘Valentine s Day 2024 Pick’. Bagadia has recommended a ‘Buy’ on the pharma stock at ₹1,450 and up to ₹1,415 for a target price of ₹1,600 to ₹1,660.
Cipla plans acquisitions and inorganic partnerships in the US market while strengthening its presence in the domestic market. The company aims to improve top line growth in Europe and expand margins in South Africa. It will focus on commercial execution, resolving USFDA observations, and growing private and select tender business. Derisking top launches and resolving regulatory issues at manufacturing plants are top priorities.
Blackstone expected to bid for over 33% stake in Cipla, marking the start of the Hamied family s exit. Cipla s Q1 profit rises.Cipla s Promoter Stake Sale to Blackstone Raises Concerns Over Indian Nationalis